Collaboration and Licensing Revenue (Tables)

9 Months Ended

Sep. 30, 2019

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summarized Collaboration and Licensing Revenues

The following table summarizes the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and nine months ended September 30, 2019 and 2018.



	Three Months Ended September 30,				Nine Months Ended September 30,
	2019		2018		2019		2018
ZIOPHARM Oncology, Inc.	$	431	$	4,826	$	2,130	$	13,626
Ares Trading S.A.	—		1,576		—		7,525
Oragenics, Inc.	231		705		615		867
Intrexon T1D Partners, LLC	—		368		—		2,399
Intrexon Energy Partners, LLC	823		1,329		2,596		3,345
Intrexon Energy Partners II, LLC	293		754		1,217		1,685
Surterra Holdings, Inc.	1,022		—		1,182		—
Genopaver, LLC	494		689		1,186		3,076
Fibrocell Science, Inc.	402		391		3,247		1,015
Persea Bio, LLC	1,083		199		621		714
Harvest start-up entities (1)	100		2,691		4,862		11,792
Other	1,306		796		3,596		5,578
Total	$	6,185	$	14,324	$	21,252	$	51,622

(1)

For the three and nine months ended September 30, 2019 and 2018, revenues recognized from collaborations with Harvest start-up entities include: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc. For the nine months ended September 30, 2018, revenues recognized from collaborations with Harvest start-up entities also include Genten Therapeutics, Inc. and CRS Bio, Inc.

Summary of Deferred Revenue

Deferred revenue consists of the following:



	September 30, 2019		December 31, 2018
Collaboration and licensing agreements	$	74,431	$	63,284
Prepaid product and service revenues	3,054		2,933
Other	1,639		3,547
Total	$	79,124	$	69,764
Current portion of deferred revenue	$	12,764	$	15,554
Long-term portion of deferred revenue	66,360		54,210
Total	$	79,124	$	69,764

Summary of Deferred Revenue by Collaborator

The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant counterparty to a collaboration or licensing agreement as of September 30, 2019 and December 31, 2018, including the estimated remaining performance period as of September 30, 2019.



	Average Remaining Performance Period (Years)	September 30, 2019		December 31, 2018
ZIOPHARM Oncology, Inc.	0.0	$	—	$	1,214
Oragenics, Inc.	4.7	5,463		5,810
Intrexon Energy Partners, LLC	4.5	8,362		10,267
Intrexon Energy Partners II, LLC	5.2	12,843		14,060
Surterra Holdings, Inc.	8.7	13,987		—
Genopaver, LLC	4.5	789		1,175
Fibrocell Science, Inc.	5.1	18,102		17,519
Persea Bio, LLC	5.3	3,553		2,697
Harvest start-up entities (1)	5.4	6,993		7,644
Other	1.7	4,297		2,898
Total		$	74,389	$	63,284

(1)

As of September 30, 2019 and December 31, 2018, the balance of deferred revenue for collaborations with Harvest start-up entities includes: Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and AD Skincare, Inc.